MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This interaction competitively inhibits myeloid cell leukemia 1’s pro-survival function in chronic myeloid leukemia cells, thereby liberating BAK from myeloid cell leukemia 1 binding.